Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ADAP Adaptimmune Therapeutics

Watchlist
2.110
-0.090-4.09%
Close 11/28 16:00 ET
2.1100.0000.00%
Post Mkt Price 11/28 16:01 ET
High
2.295
Open
2.200
Turnover
619.84K
Low
2.090
Pre Close
2.200
Volume
284.19K
Market Cap
345.68M
P/E(TTM)
Loss
52wk High
4.165
Shares
163.83M
P/E(Static)
Loss
52wk Low
1.010
Float Cap
182.11M
Bid/Ask %
25.00%
Historical High
21.570
Shs Float
86.31M
Volume Ratio
0.66
Historical Low
0.709
Dividend TTM
--
Div Yield TTM
--
P/B
3.05
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.33%
Amplitude
9.32%
Avg Price
2.181
Lot Size
1
Float Cap
182.11M
Bid/Ask %
25.00%
Historical High
21.570
Shs Float
86.31M
Volume Ratio
0.66
Historical Low
0.709
Dividend TTM
--
P/B
3.05
Dividend LFY
--
Turnover Ratio
0.33%
Amplitude
9.32%
Avg Price
2.181
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
CEO: Mr. Adrian Rawcliffe
Market: NASDAQ
Listing Date: 05/06/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist